-- Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $3.3M, vs. Street Est of $5.78M
7:01AM ET 5/09/2022 MT Newswires...
Quotes Snapshot > DTIL
Precision BioSciences Inc DTIL:NASDAQ
Last Price$1.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.65 (1)
Ask (Size)$1.69 (1)
Day Low / HighN/A - N/A
Volume201.00
Read more news Recent News
Goldman Sachs Adjusts Precision BioSciences' Price Target to $5 from $12, Keeps Neutral Rating
10:52AM ET 3/16/2022 MT NewswiresPrecision BioSciences (DTIL) has an average rating of outperform and price targets ranging from $5 to $20, according to analysts polled by Capital IQ. (MT...
Precision BioSciences FY 2021 Loss Narrows, Revenue Increases; Shares Fall
12:31PM ET 3/15/2022 MT NewswiresPrecision BioSciences (DTIL) reported a 2021 net loss Tuesday of $0.52 per diluted share, compared with a loss of $2.09 per share a year earlier. Analysts...
BTIG Adjusts Precision BioSciences' Price Target to $20 From $16, Reiterates Buy Rating
9:37AM ET 12/13/2021 MT NewswiresPrecision BioSciences (DTIL) has an average rating of outperform and price targets ranging from $11 to $24, according to analysts polled by Capital IQ. (MT...
View all Commentary and Analysis
Precision Bio: Another CAR-T Laggard With No Solid Prospects
1:36PM ET 5/09/2022 Seeking AlphaCFO Trading Anomaly For April: Revealing Top Insider Buys In Declining Markets
11:10AM ET 4/19/2022 Seeking AlphaGenomic Medicine 2021: (Happy To) Turn The Page
9:33PM ET 1/04/2022 Seeking AlphaPrecision BioSciences (DTIL) Presents At 2021 ASH: Allogeneic CAR T Pipeline Update - Slideshow
12:34PM ET 12/15/2021 Seeking AlphaCompany Profile
Business DescriptionPrecision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC. View company web site for more details
| Address | Dibrell Building Durham, North Carolina 27701 |
| Phone | +1.919.314.5512 |
| Number of Employees | 127 |
| Recent SEC Filing | 05/12/2022 4 |
| President, Chief Executive Officer & Director | Michael Amoroso |
| Vice President-Operations & Information Technology | Sinu Bhandaru |
| Chief Financial Officer | John Alexander Kelly |
| Chief Technology Officer | Jeff Smith |
Company Highlights
| Price Open | $1.58 |
| Previous Close | $1.59 |
| 52 Week Range | $1.49 - 14.38 |
| Market Capitalization | $98.9 M |
| Shares Outstanding | 62.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/11/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.75 |
| Beta vs. S&P 500 | N/A |
| Revenue | $10.9 M |
| Net Profit Margin | -34.69% |
| Return on Equity | -45.55% |
Analyst Ratings as of 05/05/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |